Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MariMedMRMD -0.23% Receivables Turnover is 4.26 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 950 Drug Manufacturers companies, MariMed ranks better than 94.63% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. MariMed's Revenue for the
three
months ended in Mar. 2026 was $39.5 Mil. MariMed's average Accounts Receivable for the
three
months ended in Mar. 2026 was $9.3 Mil.
Hence, MariMed's Receivables Turnover for the
three
months ended in Mar. 2026 was 4.26.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
MariMed Receivables Turnover Related Terms
MariMed Receivables Turnover Historical Data
* Premium members only.
The historical data trend for MariMed's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRMD vs RMTI, CPHI, TXMD: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where MariMed's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed (MRMD) has a Receivables Turnover of 4.26 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #51 out of 950 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is MariMed's Receivables Turnover too high?
MariMed's current Receivables Turnover is 4.26. The Drug Manufacturers industry median Receivables Turnover is 5.07. MariMed's value of 4.26 is 16% below this industry median. Based on the distribution chart, MariMed ranks #51 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MariMed's Receivables Turnover compare to RMTI and CPHI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #51 out of 950 companies for Receivables Turnover. This places MariMed in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. MariMed's value of 4.26 is 16% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MariMed's current Receivables Turnover of 4.26 is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current Receivables Turnover is 4.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 58.8% below its estimated fair value. The current Receivables Turnover is 4.26 and 16% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For MariMed (MRMD), the current Receivables Turnover is 4.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 
